INDUSTRY TRENDS: BY THE NUMBERS Compiled by Cari Kraft, Jacobs Management Group, Inc.
$842B $629B
Global drug sales by 2024 Over the next five years, global drug sales are expected to climb by 6.9% CAGR (compound annual growth rate), growing from this year’s $629B to $842B in 2024. Source: Evaluate Pharma World Preview 2018, Outlook to 2024
$69.82B
Total R&D expenditures by U.S. companies in 2018 United States healthcare companies spent over $69 billion in research and development last year, followed by Switzerland ($20.95B), Germany ($13.34B), the UK ($11.01B), and France ($6.95B). This was approximately 19.26% of revenue for U.S. companies. Johnson & Johnson spent the most, at $10.8B. Source: Zymewire, “Big Pharma R&D Spend Fiscal Year 2018,” July 2019
88.7% 39 | HS&M SEPTEMBER/OCTOBER 2019
Healthcare Quality and Access Rating for U.S. The Kaiser Family Foundation compared industrialized countries in terms of their Healthcare Quality and Access Index Rating (HAQ), and found that the Netherlands came in first, at 96.1%, followed by Australia, Sweden, Japan, Austria, Germany, France and the United Kingdom. The United States trailed all of those, with an 88.7% rating. Source: Kaiser Family Foundation, “Measuring performance on the Healthcare Access and Quality Index for 195 countries,” The Lancet, 23 May 2018
